查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971312

朊病毒疾病治療市場－全球產業規模、佔有率、趨勢、機會與預測：按類型、藥物、地區和競爭格局分類，2021-2031年

Prion Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity & Forecast Segmented By Type (Human Prion Diseases, Animal Prion Diseases), By Drug (Antidepressant, Antipsychotic Agents), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球朊病毒疾病治療市場預計將從 2025 年的 51.9 億美元成長到 2031 年的 68.8 億美元，複合年成長率為 4.81%。

此領域涵蓋旨在控制或改變由異常蛋白質折疊引起的致命性神經退化性疾病（例如庫賈氏病）病程的藥物療法的開發和商業化。市場成長主要由診斷技術的進步所驅動，這些進步使得早期檢測和以反義寡核苷酸和單株抗體為中心的重點監測舉措成為可能。根據美國國家朊病毒疾病病理監測中心的數據，2024年在352例轉診病例中確診了271例特定朊病毒疾病，凸顯了對有效治療方案的持續臨床需求。

市場概覽
預測期 2027-2031
市場規模：2025年 51.9億美元
市場規模：2031年 68.8億美元
複合年成長率：2026-2031年 4.81%
成長最快的細分市場 人類朊病毒病
最大的市場 北美洲

儘管存在這些積極因素，但由於這些疾病極為罕見，市場仍面臨許多重大障礙。這種罕見性嚴重限制了符合臨床試驗條件的患者數量，阻礙了監管部門核准所需的數據收集和受試者招募，並經常導致潛在治療方法從臨床前階段到商業化的進程延誤。因此，製藥公司在這一特殊治療領域進行藥物研發投資時，面臨著巨大的財務和物流風險。

市場促進因素

公共和私人研發資金的增加正在調動關鍵資源，以降低全球朊病毒疾病治療研發的風險。政府機構和非營利組織正在加大投入，加速臨床前研究，以滿足這些致命疾病對有效治療標靶的迫切需求。例如，根據美國衛生與公眾服務部的報告，美國國立衛生研究院 (NIH) 將於 2025 年向博德研究所津貼476,359 美元，用於支持先進的基因組學研究。除了公共投資外，私營非營利部門也在加大力度，彌合從發現到藥物開發的差距。克雅氏病基金會在 2025 年 1 月的津貼申請開放公告中宣布，將向專門針對人類朊病毒疾病的研究計劃提供最高 10 萬美元的研究津貼。

同時，新型免疫療法和基因療法的湧現展現了緩解疾病介入的巨大潛力。研究機構正超越症狀治療，利用反義寡核苷酸和鹼基編輯等技術靶向異常蛋白的產生，早期研究證實了令人鼓舞的結果。 2025年4月，《哈佛公報》發表了報導，報導了一種新的基因編輯策略降低了毒性蛋白水平，並將接受治療的小鼠的壽命延長了52%。這些進展凸顯了朊病毒疾病治療方法開發平臺的成熟度，以及在實現首個朊病毒疾病根治性治療方法方面所取得的競爭優勢。

市場挑戰

合格臨床實驗參加者的短缺是市場擴張的主要障礙，並從根本上阻礙了潛在治療方法的臨床開發進程。與較常見的神經退化性疾病不同，朊病毒病患者群體地域分散且規模極小，難以招募符合監管部門核准所需的具有統計意義的隊列。這種分散性迫使製藥開發商設立眾多國際臨床實驗中心以確保達到最低參與者數量，這顯著增加了營運成本和後勤複雜性。此外，由於這些疾病進展迅速，許多患者在確診時已不再符合試驗條件，導致篩檢失敗率高，並進一步延誤了研究的完成。

患者群體的這種固有限制直接限制了商業性興趣和投資。據克雅氏病基金會（CJD Foundation）稱，即使到2024年，美國每年新增病例數仍將維持在500例左右。如此有限的目標市場使得生物製藥公司面臨不利的風險回報比，因為很難證明藥物研發的高昂固定成本與有限患者群體帶來的預期收益之間的合理性。因此，這種情況常常導致一些有前景的候選藥物在早期研發階段停滯不前，無法進入上市所需的臨床實驗階段。

市場趨勢

人工智慧 (AI) 在朊病毒疾病藥物研發中的應用，透過解析異常蛋白複雜的結構動態，從根本上改變了治療標靶的識別方式。先進的機器學習演算法能夠預測 PrPSc（異常朊病毒蛋白）的瞬態結構，這在以前由於缺乏高解析度結構數據而十分困難，並且還能識別小分子的隱藏結合位點。這種計算方法顯著縮短了先導化合物的最佳化週期，並透過在物理合成之前篩選候選化合物，提高了臨床成功的機率。在 2026 年 1 月發布的一份關於與 Unravel Biosciences 合作的新聞稿中，EvoGene 預測，將其生成式 AI 平台整合到開發平臺中，將加速藥物發現進程，並直接促成計劃於 2026 年推出的四項針對神經退化性疾病的新臨床試驗。

同時，將RT-QuIC生物標記整合到臨床試驗設計中，可以有效解決患者分層和招募的瓶頸問題。透過將即時震盪誘導轉化試驗（RT-QuIC）作為主要入組標準，研發人員可以確保在先兆期識別出合格的受試者，從而減少篩檢失敗，並保證研究隊列具有活躍的朊病毒種子活性。這種精準性對於證明治療效果至關重要，尤其對於那些病情惡化迅速、標準臨床終點無法捕捉療效的患者族群。根據梅奧診所研究所2025年2月發表的一篇報導，腦脊髓液檢測的廣泛臨床應用將使醫護人員能夠在患者喪失功能獨立性之前（通常在兩年內）確認診斷並確定其合格試驗資格。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球朊病毒疾病治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（人類朊病毒病、動物朊病毒病）
    • 依藥物類型（抗憂鬱劑、抗精神病藥）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美朊病毒病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲朊病毒疾病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區朊病毒疾病療法的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲朊病毒病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲朊病毒病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球朊病毒疾病治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Fresenius SE & Co. KGaA
  • Elite Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • Novartis AG
  • Merck KGaA
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Cipla Ltd
  • Teva Pharmaceuticals Industries Ltd
  • Abbott Laboratories

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17004

The Global Prion Disease Treatment Market is projected to expand from USD 5.19 Billion in 2025 to USD 6.88 Billion by 2031, registering a compound annual growth rate of 4.81%. This sector encompasses the development and commercialization of pharmaceutical therapies designed to manage or alter the course of fatal neurodegenerative disorders arising from misfolded proteins, such as Creutzfeldt-Jakob Disease. Market growth is largely fueled by improvements in diagnostic technologies that allow for earlier detection, alongside focused research initiatives centering on antisense oligonucleotides and monoclonal antibodies. According to the National Prion Disease Pathology Surveillance Center, 271 specific prion disease cases were confirmed from 352 referrals in 2024, emphasizing the persistent clinical necessity for effective therapeutic options.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.19 Billion
Market Size 2031USD 6.88 Billion
CAGR 2026-20314.81%
Fastest Growing SegmentHuman Prion Diseases
Largest MarketNorth America

Despite these positive drivers, the market confronts substantial obstacles due to the extreme rarity of these diseases, which severely restricts the pool of patients eligible for clinical trials. This scarcity hampers recruitment efforts and the data collection necessary for regulatory approval, frequently stalling the movement of potential therapies from preclinical stages to commercial release. Consequently, pharmaceutical firms encounter significant financial and logistical hazards when investing in drug development for this specialized therapeutic area.

Market Driver

The increase in public and private R&D funding is mobilizing critical resources to reduce the risks associated with therapeutic development in the Global Prion Disease Treatment Market. Government agencies and non-profit organizations are boosting financial commitments to accelerate preclinical research, addressing the urgent requirement for viable targets in these fatal conditions. For example, the U.S. Department of Health and Human Services reported that in 2025, the National Institutes of Health granted $476,359 to the Broad Institute to support advanced genomic research. Complementing this public investment, the private non-profit sector is scaling up efforts to bridge the gap between discovery and drug development; the CJD Foundation announced in its January 2025 'Request for 2024-25 Grant Applications' that it would award research grants of up to $100,000 for projects specifically focused on human prion diseases.

Concurrently, the emergence of novel immunotherapy and gene therapy pipelines is introducing potential disease-modifying interventions. Research entities are moving beyond symptomatic relief, utilizing modalities such as antisense oligonucleotides and base editing to target the fundamental production of misfolded proteins, with early studies showing promising efficacy. In April 2025, the Harvard Gazette reported in 'Team hits milestone toward prion disease treatment' that a new gene-editing strategy successfully lowered toxic protein levels and extended the lifespans of treated mice by 52 percent. These advancements highlight the maturation of the pipeline and the competitive drive to deliver the first curative treatments for prion disorders.

Market Challenge

The scarcity of eligible trial participants presents a formidable barrier to market expansion, fundamentally disrupting the clinical development timeline for potential therapies. Unlike more common neurodegenerative disorders, the patient population for prion diseases is geographically dispersed and exceptionally small, complicating the recruitment of statistically significant cohorts required for regulatory approval. This fragmentation compels pharmaceutical developers to establish numerous international trial sites to secure a minimal number of participants, a requirement that exponentially increases operational costs and logistical complexity. Furthermore, the rapid progression of these conditions often renders patients ineligible for participation by the time a definitive diagnosis is confirmed, resulting in high screen-failure rates that further delay study completion.

This inherent volume constraint directly limits commercial interest and investment. According to the CJD Foundation, in 2024, the annual incidence in the United States remained limited to nearly 500 new cases per year. Such a restricted addressable market creates an unfavorable risk-to-reward ratio for biopharmaceutical entities, as the high fixed costs of drug development are difficult to justify against the projected revenue from such a finite patient base. Consequently, this dynamic frequently stalls promising candidates in early-stage research, preventing them from advancing to the pivotal trials necessary for market entry.

Market Trends

The application of Artificial Intelligence in prion drug discovery is fundamentally reshaping the identification of therapeutic targets by decoding the complex structural dynamics of misfolded proteins. Advanced machine learning algorithms are now being utilized to predict the transient conformations of PrPSc and identify cryptic binding pockets for small molecules, a task previously hindered by the lack of high-resolution structural data. This computational approach significantly compresses the timeline for lead optimization and improves the probability of clinical success by filtering candidates before physical synthesis. According to Evogene Ltd., in a January 2026 press release regarding their collaboration with Unravel Biosciences, the integration of generative AI platforms into the development pipeline is projected to accelerate the discovery process, directly contributing to the initiation of four new clinical trials for neurodegenerative conditions starting in 2026.

Simultaneously, the integration of RT-QuIC biomarkers in clinical trial design is addressing the critical bottleneck of patient stratification and recruitment. By incorporating Real-Time Quaking-Induced Conversion assays as a primary inclusion criterion, developers can now definitively identify eligible participants at the prodromal stage, thereby reducing screen failures and ensuring that study cohorts exhibit active prion seeding activity. This precision is vital for demonstrating therapeutic efficacy in a rapidly deteriorating patient base where standard clinical endpoints are often too slow to capture treatment effects. According to a February 2025 article by Mayo Clinic Laboratories, the widespread clinical deployment of this cerebrospinal fluid assay now enables providers to confirm a diagnosis and determine trial eligibility before patients lose functional independence, a period often spanning less than two years.

Key Market Players

  • Fresenius SE & Co. KGaA
  • Elite Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • Novartis AG
  • Merck KGaA
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Cipla Ltd
  • Teva Pharmaceuticals Industries Ltd
  • Abbott Laboratories

Report Scope

In this report, the Global Prion Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prion Disease Treatment Market, By Type

  • Human Prion Diseases
  • Animal Prion Diseases

Prion Disease Treatment Market, By Drug

  • Antidepressant
  • Antipsychotic Agents

Prion Disease Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prion Disease Treatment Market.

Available Customizations:

Global Prion Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prion Disease Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Human Prion Diseases, Animal Prion Diseases)
    • 5.2.2. By Drug (Antidepressant, Antipsychotic Agents)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Prion Disease Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Drug
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Prion Disease Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Drug
    • 6.3.2. Canada Prion Disease Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Drug
    • 6.3.3. Mexico Prion Disease Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Drug

7. Europe Prion Disease Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Drug
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Prion Disease Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Drug
    • 7.3.2. France Prion Disease Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Drug
    • 7.3.3. United Kingdom Prion Disease Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Drug
    • 7.3.4. Italy Prion Disease Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Drug
    • 7.3.5. Spain Prion Disease Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Drug

8. Asia Pacific Prion Disease Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Drug
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Prion Disease Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Drug
    • 8.3.2. India Prion Disease Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Drug
    • 8.3.3. Japan Prion Disease Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Drug
    • 8.3.4. South Korea Prion Disease Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Drug
    • 8.3.5. Australia Prion Disease Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Drug

9. Middle East & Africa Prion Disease Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Drug
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Prion Disease Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Drug
    • 9.3.2. UAE Prion Disease Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Drug
    • 9.3.3. South Africa Prion Disease Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Drug

10. South America Prion Disease Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Drug
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Prion Disease Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Drug
    • 10.3.2. Colombia Prion Disease Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Drug
    • 10.3.3. Argentina Prion Disease Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Drug

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Prion Disease Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Fresenius SE & Co. KGaA
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Elite Pharmaceuticals Inc
  • 15.3. Ionis Pharmaceuticals Inc
  • 15.4. Novartis AG
  • 15.5. Merck KGaA
  • 15.6. AstraZeneca PLC
  • 15.7. Bristol-Myers Squibb Company
  • 15.8. Cipla Ltd
  • 15.9. Teva Pharmaceuticals Industries Ltd
  • 15.10. Abbott Laboratories

16. Strategic Recommendations

17. About Us & Disclaimer